Table 3.

Sensitivity analyses of the primary outcome: time to resolution of shock

Metaraminol and norepinephrine*	Norepinephrine*	P value†	HR (95% CI)‡	SHR (95% CI)§
Full sample (n=286)
44 (28 to 66)	27 (14 to 63)	<0.01	1.24 (0.96 to 1.60)	1.16 (0.90 to 1.49)
Subset with sepsis (n=131)
50 (31 to 76)	41 (21 to 75)	0.15	1.09 (0.74 to 1.60)	1.04 (0.71 to 1.51)
Subset without other concurrent vasopressors or inotropes (n=201)
41 (26 to 60)	22 (13 to 41)	<0.01	1.55 (1.16 to 2.07)	1.54 (1.14 to 2.09)
Subset with sepsis and without other concurrent vasopressors or inotropes (n=86)
45 (29 to 61)	26 (14 to 58)	0.02	1.32 (0.84 to 2.07)	1.42 (0.90 to 2.23)

*Reported as median (IQR) hours from Kaplan-Meier analysis.

†Wilcoxon test.

‡HR from Cox regression.

§Sub-hazard ratio with death as a competing risk.